The glycosylation pattern of TA-MUC1 in tumors differs from its normal form, making it a key indicator of the disease. Related News | How Does AI Help In Early Detection and Treatment Of Cancer?

SPARC seeks US FDA nod to start phase 1 trial of SBO-154 to treat advanced solid tumours: Our Bureau, Mumbai Monday, March 31, 2025, 12:15 Hrs [IST] Sun Pharma Advanced Research C ...

Phase 1/2 clinical trial evaluating the proprietary combination to be run under PDS Biotech’s Cooperative Research and Development Agreement with the National Cancer Institute Second Versamune ® ...

“Targeting MUC1 with an immunotherapy that elicits a strong and durable tumor-infiltrating T-cell response could represent a major advancement in cancer treatment.” The National Cancer ...

Mumbai: Sun Pharma Advanced Research Company Ltd. has announced submission of an Investigational New Drug (IND) application ...

DATROWAY ® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC ...

E3−] platform to produce anti-cancer vaccines targeted at a number of antigens, including carcinoembryonic antigen, brachyury, HER2 and MUC1. These vaccines are currently undergoing clinical ...

Sun Pharma Advanced Research Company (SPARC) said that it has submitted an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for its antibody-drug conjugate ...

“Targeting MUC1 with an immunotherapy that elicits a strong and durable tumor-infiltrating T-cell response could represent a major advancement in cancer treatment.” The National Cancer Institute (“NCI ...